Amicus Therapeutics (NASDAQ:FOLD) Insider David Michael Clark Sells 25,643 Shares of Stock

by · The Cerbat Gem

Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) insider David Michael Clark sold 25,643 shares of the stock in a transaction on Monday, December 15th. The stock was sold at an average price of $11.00, for a total value of $282,073.00. Following the transaction, the insider directly owned 271,332 shares in the company, valued at approximately $2,984,652. This represents a 8.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

David Michael Clark also recently made the following trade(s):

  • On Monday, November 24th, David Michael Clark sold 25,643 shares of Amicus Therapeutics stock. The stock was sold at an average price of $10.10, for a total value of $258,994.30.
  • On Tuesday, November 4th, David Michael Clark sold 25,643 shares of Amicus Therapeutics stock. The stock was sold at an average price of $9.51, for a total transaction of $243,864.93.

Amicus Therapeutics Trading Down 2.2%

FOLD stock traded down $0.24 on Thursday, hitting $10.76. 220,948 shares of the company were exchanged, compared to its average volume of 4,295,684. Amicus Therapeutics, Inc. has a twelve month low of $5.51 and a twelve month high of $11.14. The company has a debt-to-equity ratio of 1.70, a current ratio of 2.99 and a quick ratio of 2.09. The business’s fifty day moving average is $9.31 and its two-hundred day moving average is $7.75. The stock has a market capitalization of $3.32 billion, a price-to-earnings ratio of -268.03 and a beta of 0.46.

Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.05. The company had revenue of $169.06 million during the quarter, compared to analysts’ expectations of $165.24 million. Amicus Therapeutics had a negative net margin of 2.35% and a positive return on equity of 6.95%. The business’s quarterly revenue was up 19.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.10 EPS. As a group, research analysts forecast that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on FOLD shares. JPMorgan Chase & Co. boosted their price objective on shares of Amicus Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Zacks Research raised shares of Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. Wall Street Zen upgraded Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Amicus Therapeutics in a research report on Monday. Finally, The Goldman Sachs Group boosted their price objective on Amicus Therapeutics from $9.00 to $11.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.29.

Get Our Latest Report on FOLD

Institutional Investors Weigh In On Amicus Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in Amicus Therapeutics during the second quarter worth about $18,540,000. Invesco Ltd. boosted its stake in Amicus Therapeutics by 4.1% in the first quarter. Invesco Ltd. now owns 2,661,394 shares of the biopharmaceutical company’s stock valued at $21,717,000 after acquiring an additional 105,856 shares during the period. Capital Fund Management S.A. grew its holdings in shares of Amicus Therapeutics by 408.8% during the first quarter. Capital Fund Management S.A. now owns 312,561 shares of the biopharmaceutical company’s stock valued at $2,550,000 after purchasing an additional 251,134 shares during the last quarter. Jump Financial LLC raised its position in shares of Amicus Therapeutics by 246.3% during the 2nd quarter. Jump Financial LLC now owns 1,406,563 shares of the biopharmaceutical company’s stock worth $8,060,000 after purchasing an additional 1,000,395 shares during the period. Finally, Advantage Alpha Capital Partners LP acquired a new stake in shares of Amicus Therapeutics during the 2nd quarter worth approximately $201,000.

Amicus Therapeutics Company Profile

(Get Free Report)

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

Recommended Stories